Literature DB >> 20065632

Motavizumab.

Oya Cingoz1.   

Abstract

Motavizumab (MEDI-524, Numax) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20065632      PMCID： PMC2759493          DOI： 10.4161/mabs.1.5.9496

Source DB:  PubMed          Journal:  MAbs        ISSN： 1942-0862            Impact factor:   5.857


  8 in total

1.  Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.

Authors:  Herren Wu; David S Pfarr; Ying Tang; Ling-Ling An; Nita K Patel; Jeffry D Watkins; William D Huse; Peter A Kiener; James F Young
Journal:  J Mol Biol       Date:  2005-07-01       Impact factor: 5.469

2.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

Authors:  S Johnson; C Oliver; G A Prince; V G Hemming; D S Pfarr; S C Wang; M Dormitzer; J O'Grady; S Koenig; J K Tamura; R Woods; G Bansal; D Couchenour; E Tsao; W C Hall; J F Young
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

3.  Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.

Authors:  Asunción Mejías; Susana Chávez-Bueno; Ana María Ríos; Mónica Fonseca Aten; Brett Raynor; Estrella Peromingo; Perla Soni; Kurt D Olsen; Peter A Kiener; Ana María Gómez; Hasan S Jafri; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 4.  Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.

Authors:  H Wu; D S Pfarr; G A Losonsky; P A Kiener
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

5.  Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Authors:  Herren Wu; David S Pfarr; Syd Johnson; Yambasu A Brewah; Robert M Woods; Nita K Patel; Wendy I White; James F Young; Peter A Kiener
Journal:  J Mol Biol       Date:  2007-02-20       Impact factor: 5.469

6.  Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study.

Authors:  C B Hall; J T McBride; E E Walsh; D M Bell; C L Gala; S Hildreth; L G Ten Eyck; W J Hall
Journal:  N Engl J Med       Date:  1983-06-16       Impact factor: 91.245

7.  Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.

Authors:  Leonard E Weisman
Journal:  Curr Opin Mol Ther       Date:  2009-04

8.  Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.

Authors:  Katia Abarca; Elizabeth Jung; Pilar Fernández; Liang Zhao; Brian Harris; Edward M Connor; Genevieve A Losonsky
Journal:  Pediatr Infect Dis J       Date:  2009-04       Impact factor: 2.129
  8 in total
  10 in total

1.  Respiratory syncytial virus prevention in children with congenital heart disease: who and how?

Authors:  Nam Kyun Kim; Jae Young Choi
Journal:  Korean J Pediatr       Date:  2011-05-31

2.  Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus.

Authors:  Mridula Rani; Meagan Bolles; Eric F Donaldson; Thomas Van Blarcom; Ralph Baric; Brent Iverson; George Georgiou
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

3.  A Mesenchymal-Epithelial Transition Factor-Agonistic Antibody Accelerates Cirrhotic Liver Regeneration and Improves Mouse Survival Following Partial Hepatectomy.

Authors:  Kuai Ma; Weitao Que; Xin Hu; Wen-Zhi Guo; Er-Li Gu; Liang Zhong; Virginia Morello; Manuela Cazzanti; Paolo Michieli; Terumi Takahara; Xiao-Kang Li
Journal:  Liver Transpl       Date:  2021-10-12       Impact factor: 6.112

4.  Antiviral activity of diarylheptanoid stereoisomers against respiratory syncytial virus in vitro and in vivo.

Authors:  Katsuhiko Konno; Motofumi Miura; Masaharu Toriyama; Shigeyasu Motohashi; Rie Sawamura; Wataru Watanabe; Hiroki Yoshida; Masahiko Kato; Ryuichi Yamamoto; Ken Yasukawa; Masahiko Kurokawa
Journal:  J Nat Med       Date:  2013-01-24       Impact factor: 2.343

5.  Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a protocol for a systematic review.

Authors:  Lauren Alexandra Quinn; Michael D Shields; Helen E Groves
Journal:  Syst Rev       Date:  2019-12-19

6.  Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a systematic review.

Authors:  Lauren Alexandra Quinn; Michael D Shields; Ian Sinha; Helen E Groves
Journal:  Syst Rev       Date:  2020-11-25

Review 7.  Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies.

Authors:  Zifang Shang; Shuguang Tan; Dongli Ma
Journal:  Int J Biol Sci       Date:  2021-09-27       Impact factor: 6.580

Review 8.  Protein and Peptide Substances in the Treatment of Respiratory Syncytial Infection: Current State.

Authors:  Anna A Shtro; Galina D Petukhova; Aleksandra S Romanova
Journal:  Molecules       Date:  2022-03-31       Impact factor: 4.411

Review 9.  Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections.

Authors:  Pardis Mokhtary; Zeinab Pourhashem; Akram Abouei Mehrizi; Claudia Sala; Rino Rappuoli
Journal:  Biomedicines       Date:  2022-08-02

10.  Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens.

Authors:  George Ueda; Aleksandar Antanasijevic; Jorge A Fallas; William Sheffler; Jeffrey Copps; Daniel Ellis; Geoffrey B Hutchinson; Adam Moyer; Anila Yasmeen; Yaroslav Tsybovsky; Young-Jun Park; Matthew J Bick; Banumathi Sankaran; Rebecca A Gillespie; Philip Jm Brouwer; Peter H Zwart; David Veesler; Masaru Kanekiyo; Barney S Graham; Rogier W Sanders; John P Moore; Per Johan Klasse; Andrew B Ward; Neil P King; David Baker
Journal:  Elife       Date:  2020-08-04       Impact factor: 8.140
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.